Adverse drug events: identification and attribution.

Area of Science:

• Pharmacovigilance
• Drug Safety Evaluation
• Clinical Pharmacology

Background:

• Limited human safety data available at drug marketing.
• Post-marketing surveillance is essential for comprehensive drug safety profiles.
• Adverse drug event definitions vary based on intended use (clinical vs. scientific).

Purpose of the Study:

• To discuss the selection of appropriate adverse drug event definitions.
• To examine the scope of safety data at drug marketing.
• To propose methods for post-marketing safety data collection and causality assessment.

Main Methods:

• Review of existing definitions for adverse drug events.
• Analysis of post-marketing surveillance systems (e.g., FDA's Spontaneous Reporting System).
• Discussion of criteria for establishing causal relationships between drugs and adverse events.

Main Results:

• Different definitions of adverse drug events are suitable for clinical and scientific purposes.
• Post-marketing data collection methods include spontaneous reporting, large population studies, and targeted research.
• Epidemiologic evidence is generally required for regulatory actions like drug recalls.

Conclusions:

• Tailoring adverse drug event definitions is critical for accurate assessment.
• Robust post-marketing surveillance is necessary to supplement initial drug safety data.
• Causality judgments for adverse drug events require rigorous data and appropriate criteria, often relying on epidemiologic evidence.